Cargando…
Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles
Cyclosporine A (CsA) is an immunosuppressant frequently used in the therapy of autoimmune disorders, including skin-related diseases. Aiming towards topical delivery, CsA was successfully incorporated into lipid nanoparticles of Lipocire DM and Pluronic F-127 using the hot homogenization method. Two...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780175/ https://www.ncbi.nlm.nih.gov/pubmed/31461853 http://dx.doi.org/10.3390/nano9091204 |
_version_ | 1783457068065226752 |
---|---|
author | Essaghraoui, Abderrazzaq Belfkira, Ahmed Hamdaoui, Bassou Nunes, Cláudia Lima, Sofia A. Costa Reis, Salette |
author_facet | Essaghraoui, Abderrazzaq Belfkira, Ahmed Hamdaoui, Bassou Nunes, Cláudia Lima, Sofia A. Costa Reis, Salette |
author_sort | Essaghraoui, Abderrazzaq |
collection | PubMed |
description | Cyclosporine A (CsA) is an immunosuppressant frequently used in the therapy of autoimmune disorders, including skin-related diseases. Aiming towards topical delivery, CsA was successfully incorporated into lipid nanoparticles of Lipocire DM and Pluronic F-127 using the hot homogenization method. Two different nanocarriers were optimized: solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) where oleic acid was the liquid lipid. The developed nanoparticles showed mean sizes around 200 nm, a negative surface charge, and drug entrapment efficiencies around 85% and 70% for SLNs and NLCs, respectively. The spherical CsA-loaded lipid nanoparticles were stable for 9 weeks when stored at room temperature, and exhibited in vitro pH-dependent release under skin mimetic conditions, following the Peppas–Korsmeyer model. CsA, when loaded in SLNs, was safe to be used up to 140 μg mL(−1) in fibroblasts and keratinocytes, while CsA-loaded NLCs and free drug exhibited IC(50) values of 55 and 95 μg mL(−1) (fibroblasts) and 28 and 30 μg mL(−1) (keratinocytes), respectively. The developed SLNs were able to retain the drug in pork skin with a reduced permeation rate in relation to NLCs. These findings suggest that SLNs are a potential alternative to produce stable and safe CsA nanocarriers for topical administration. |
format | Online Article Text |
id | pubmed-6780175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67801752019-10-30 Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles Essaghraoui, Abderrazzaq Belfkira, Ahmed Hamdaoui, Bassou Nunes, Cláudia Lima, Sofia A. Costa Reis, Salette Nanomaterials (Basel) Article Cyclosporine A (CsA) is an immunosuppressant frequently used in the therapy of autoimmune disorders, including skin-related diseases. Aiming towards topical delivery, CsA was successfully incorporated into lipid nanoparticles of Lipocire DM and Pluronic F-127 using the hot homogenization method. Two different nanocarriers were optimized: solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) where oleic acid was the liquid lipid. The developed nanoparticles showed mean sizes around 200 nm, a negative surface charge, and drug entrapment efficiencies around 85% and 70% for SLNs and NLCs, respectively. The spherical CsA-loaded lipid nanoparticles were stable for 9 weeks when stored at room temperature, and exhibited in vitro pH-dependent release under skin mimetic conditions, following the Peppas–Korsmeyer model. CsA, when loaded in SLNs, was safe to be used up to 140 μg mL(−1) in fibroblasts and keratinocytes, while CsA-loaded NLCs and free drug exhibited IC(50) values of 55 and 95 μg mL(−1) (fibroblasts) and 28 and 30 μg mL(−1) (keratinocytes), respectively. The developed SLNs were able to retain the drug in pork skin with a reduced permeation rate in relation to NLCs. These findings suggest that SLNs are a potential alternative to produce stable and safe CsA nanocarriers for topical administration. MDPI 2019-08-27 /pmc/articles/PMC6780175/ /pubmed/31461853 http://dx.doi.org/10.3390/nano9091204 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Essaghraoui, Abderrazzaq Belfkira, Ahmed Hamdaoui, Bassou Nunes, Cláudia Lima, Sofia A. Costa Reis, Salette Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles |
title | Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles |
title_full | Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles |
title_fullStr | Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles |
title_full_unstemmed | Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles |
title_short | Improved Dermal Delivery of Cyclosporine A Loaded in Solid Lipid Nanoparticles |
title_sort | improved dermal delivery of cyclosporine a loaded in solid lipid nanoparticles |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780175/ https://www.ncbi.nlm.nih.gov/pubmed/31461853 http://dx.doi.org/10.3390/nano9091204 |
work_keys_str_mv | AT essaghraouiabderrazzaq improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles AT belfkiraahmed improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles AT hamdaouibassou improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles AT nunesclaudia improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles AT limasofiaacosta improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles AT reissalette improveddermaldeliveryofcyclosporinealoadedinsolidlipidnanoparticles |